National Stroke Foundation

SPORANOX (itraconazole)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved March 1997

Specific Treatments:

oral thrush

General Information

SPORANOX (itraconazole) Oral solution has been approved for the treatment of painful and debilitating fungal infections of the esophagus or the mouth, commonly called thrush.

Clinical Results

In clinical studies, SPORANOX Oral Solution was as effective as current front-line therapy in healing the white plaques and raw, ulcerated lesions associated with candidiasis.

Data presented at the 11th International Conference on AIDS in Vancouver in July, comparing SPORANOX Oral Solution to fluconazole tablets, a leading treatment for thrush, showed that an average of 84% of patients with oral thrush were cured or had no visible lesions after treatment with either 7 to 14 days of SPORANOX Oral Solution (200 mg/day) or fluconazole tablets (200 mg day one, followed by 100 mg for 13 days). There were 190 patients in that trial.

Similar results were found in a double-blind randomized study of 119 patients with esophageal candidiasis. An average of 86% of patients were cured or improved with 100 mg/day of either SPORANOX Oral Solution or fluconazole tablets, administered for 21 days. Only 11% of patients on SPORANOX Oral Solution and 21% of patients on fluconazole tablets required higher doses (200 mg/day).

SPORANOX Oral Solution may also be effective in treating oral candidiasis patients who were clinical fluconazole failures. Of patients who did not show clinical improvement with fluconazole tablets (minimum 200 mg/day for at least 14 days), 55% had complete resolution of oral lesions, after 200 mg/day of SPORANOX after 200mg/day of SPORANOX Oral Solution for periods of 14 to 28 days in an open-label study of 74 patients.

Side Effects

SPORANOX Oral Solution is generally well-tolerated. Gastrointestinal upset and diarrhea are the most frequently observed adverse events at 10.3%. Other side effects include fever (6.3%). Co-administration of SPORANOX Oral Solution with terfenadine, astemizole, cisapride, oral triazolam, oral midazolam, lovastatin or simvastatin is contraindicated. SPORANOX Oral Solution and SPORANOX Capsules should not be used interchangeably. SPORANOX Capsules are not indicated for treatment of oral and esophageal candidiasis.

Additional Information

Thrush affects nearly half of all HIV-positive individuals and up to 95% of patients with AIDS. Oral and esophageal candidiasis cause painful sores in the mouth or esophagus, often causing great difficulty eating or taking medication, and leading to nutritional deficits and weight loss.